Abstract
Cytomegalovirus (CMV) is the most clinically relevant infectious agent in heart transplant (HT) recipients. Although antiviral agents used in a prophylaxis strategy seem superior to a pre-emptive approach to reduce CMV burden and its consequences, the impact of the additional anti-CMV effect of everolimus (EVE) on the benefit of antiviral prophylaxis is currently unexplored. In this study we analyzed the interaction of anti-CMV strategy and the use of EVE or mycophenolate (MMF) on the occurrence of CMV events in de novo HT recipients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
Paper Title
Journal
Date
